Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?

ABSTRACT:

Background

Sargramostim [recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF)] was approved by US FDA in 1991 to accelerate bone marrow recovery in diverse settings of bone marrow failure and is designated on the list of FDA Essential Medicines, Medical Countermeasures, and Critical Inputs. Other important biological activities including accelerating tissue repair and modulating host immunity to infection and cancer via the innate and adaptive immune systems are reported in pre-clinical models but incompletely studied in humans.

Objective

Assess safety and efficacy of sargramostim in cancer and other diverse experimental and clinical settings.

Methods and results

We systematically reviewed PubMed, Cochrane and TRIP databases for clini

SUBMITTER: Lazarus HM 

PROVIDER: S-EPMC8416151 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature